Liposomal bupivacaine is a novel local anesthetic designed for prolonged pain relief. Despite its long-acting analgesic potential, liposomal bupivacaine is significantly more expensive than other local anesthetic alternatives. The primary aim of this investigation is to examine whether or not liposomal bupivacaine provides superior pain relief or clinically significant opioid-sparing effects versus a control to justify its cost.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Periarticular infiltration of the liposomal bupivacaine with 20cc of normal saline
Periarticular infiltration of 24c of bupivacaine HCl, 0.8cc morphine, 0.3cc epinephrine, and 1cc of methylprednisolone
Miller Orthopedic Specialists
Council Bluffs, Iowa, United States
Mean visual analog scale (VAS) pain scores
Self-reported pain scores from 0=no pain to 10=severe pain
Time frame: Night of surgery
Mean visual analog scale (VAS) pain scores
Self-reported pain scores from 0=no pain to 10=severe pain
Time frame: Post-operative day 1
Mean visual analog scale (VAS) pain scores
Self-reported pain scores from 0=no pain to 10=severe pain
Time frame: Post-operative day 2
Pain assessment phone call
Subjects will be called on post-operative day three by one of the investigators of the study. Subjects will be asked to rate their current pain level from 1 to 10 and to rate their worst pain level from 1 to 10 that day.
Time frame: Post-operative day 3
Complications
Number of patients with complications
Time frame: Complications will be followed for the duration of patients' hospital stay, an expected average of 2-3 days.
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.